Regenxbio Inc (RGNX)
16.83
+0.19
(+1.14%)
USD |
NASDAQ |
May 03, 16:00
16.81
-0.02
(-0.12%)
After-Hours: 20:00
Regenxbio Revenue (TTM): 90.24M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 90.24M |
September 30, 2023 | 99.37M |
June 30, 2023 | 96.97M |
March 31, 2023 | 109.64M |
December 31, 2022 | 112.72M |
September 30, 2022 | 480.03M |
June 30, 2022 | 484.30M |
March 31, 2022 | 473.68M |
December 31, 2021 | 470.35M |
September 30, 2021 | 93.14M |
June 30, 2021 | 161.28M |
March 31, 2021 | 155.81M |
December 31, 2020 | 154.57M |
September 30, 2020 | 144.89M |
June 30, 2020 | 60.68M |
March 31, 2020 | 51.99M |
December 31, 2019 | 35.23M |
September 30, 2019 | 64.24M |
Date | Value |
---|---|
June 30, 2019 | 54.85M |
March 31, 2019 | 87.00M |
December 31, 2018 | 218.50M |
September 30, 2018 | 179.77M |
June 30, 2018 | 175.80M |
March 31, 2018 | 142.33M |
December 31, 2017 | 10.39M |
September 30, 2017 | 10.05M |
June 30, 2017 | 8.838M |
March 31, 2017 | 4.651M |
December 31, 2016 | 4.589M |
September 30, 2016 | 7.341M |
June 30, 2016 | 8.356M |
March 31, 2016 | 7.344M |
December 31, 2015 | 7.595M |
September 30, 2015 | 4.295M |
June 30, 2015 | 3.638M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
35.23M
Minimum
Dec 2019
484.30M
Maximum
Jun 2022
178.63M
Average
109.64M
Median
Mar 2023
Revenue (TTM) Benchmarks
Sarepta Therapeutics Inc | 1.403B |
Amgen Inc | 29.53B |
Gilead Sciences Inc | 27.45B |
AbbVie Inc | 54.40B |
Bristol-Myers Squibb Co | 45.53B |